Cat. No. 5281
Alternative Name: XBD173
Chemical Name: N-Ethyl-7,8-dihydro-7-methyl-8-oxo-
Biological ActivityLigand of translocator protein (TSPO, peripheral benzodiazepine receptor). Exhibits high affinity for TSPO in rat whole brain (Ki = 0.297 nM), and high potency against human and rat glial TSPO (IC50 values are 2.73 and 3.04 nM respectively). Displays no noticeable binding to a number of other receptors, transporters or ion channels. Also displays anxiolytic and antidepressant effects in rodent models, without inducing benzodiazepine-like adverse effects.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Qiu et al (2013) Repeated administration of AC-5216, a ligand for the 18kDa translocator protein, improves behavioral deficits in a mouse model of post-traumatic stress disorder. Prog.Neuropsychopharmacol.Biol.Psychiatry 45 40. PMID: 23624119.
Kita et al (2004) Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br.J.Pharmacol. 142 1059. PMID: 15249420.
If you know of a relevant reference for AC 5216 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AC 5216 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: AC 5216, supplier, AC5216, anxiolytic, anti-anxiety, antidepressant, mitochondrial, benzodiazepine, BZD, ligands, PBR, TSPO, GABAA, Tocris Bioscience, Translocator Protein Ligand products
Find multiple products by catalog number
New Products in this Area
Antiviral; active against Zika, West Nile and dengue viruses25-Hydroxycholesterol
Antiviral; also α-crystallin (cryAB) chaperoneFilipin III
Polyene antibiotic; inhibits formation of pathological isoform of prion protein
June 14 - 17, 2017
Boston, MA, USA